Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Impact BioMedicalIBO -1.57%10 Gross Margin % is 66.67% as of Jun. 2026. GuruFocus rates IBO with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 735 Biotechnology companies, Impact BioMedical ranks worse than 99.46% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Impact BioMedical had a gross margin of 66.67% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Impact BioMedical Gross Margin % Related Terms
Impact BioMedical Gross Margin % Historical Data
* Premium members only.
The historical data trend for Impact BioMedical's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Impact BioMedical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impact BioMedical Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Impact BioMedical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Impact BioMedical's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Impact BioMedical (IBO) has a Gross Margin % of 66.67% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Impact BioMedical and its competitors. According to the industry distribution chart, Impact BioMedical ranks #731 out of 735 companies in the Biotechnology industry, placing it in the top 99.5%.
Is Impact BioMedical's Gross Margin % too high?
Impact BioMedical's current Gross Margin % is 66.67%. The Biotechnology industry median Gross Margin % is 60.91. Impact BioMedical's value of 66.67% is 9.5% above this industry median. Based on the distribution chart, Impact BioMedical ranks #731 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Impact BioMedical has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Impact BioMedical's Gross Margin % compare to ATYR and MCRB?
According to the Biotechnology industry distribution chart, Impact BioMedical ranks #731 out of 735 companies for Gross Margin %. This places Impact BioMedical in the lower half of its industry. The industry median Gross Margin % is 60.91. Impact BioMedical's value of 66.67% is 9.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Impact BioMedical's current Gross Margin % of 66.67% is 9.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Impact BioMedical and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impact BioMedical's current Gross Margin % is 66.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impact BioMedical stock overvalued right now?
Impact BioMedical (IBO) has a current Gross Margin % of 66.67%. The current Gross Margin % is 66.67% and 9.5% above the Biotechnology industry median of 60.91. Impact BioMedical's overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Impact BioMedical (IBO), the current Gross Margin % is 66.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
10GF Score
Get the complete analysis for IBO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBO has been successfully added to your 
